By 2032, the cell and gene therapy market will grow from $18.8B in 2023 to $60.1B, with rapid tech advances, regulatory support, and increased investments.
AI is transforming the process of finding new drugs, speeding up procedures, increasing success rates, and opening the doors for ground-breaking therapies.
AI integration in the development of drugs accelerates research, reduces costs, and improves accuracy, significantly benefiting the pharmaceutical business.
To promote medication research and ensure safety, experts urged for more transparent AI laws and public-private collaborations at a session hosted by the FDA.
Recursion and Exscientia merge with $850M in capital, targeting at least 10 clinical readouts over 18 months, combining strengths in AI-driven drug development.
